Fundz

Immunity Bio reported raising $10.7 Million in an initial SEC Form D filing, from an offering of $10.7 Million

PUBLIC · IBRXJul 22, 2022

Amount Raised

$10.7 Million

$10.7 Million sold, per SEC Form D (first sale Jul 9, 2022)

Round Type

Venture

San DiegoBiotechnology

Who else raised in Biotechnology around the same time

Companies in the same sectors as ImmunityBio that raised within 45 days of this round, from Fundz verified event records.

  • Biotia raised $8M (Series A) on August 23, 2022.
  • LumaBridge raised an undisclosed amount (Private Equity) on August 23, 2022.
  • Freedom Biosciences raised $11M (Seed) on August 23, 2022.
  • eTheRNA raised $42M (Series B) on August 23, 2022.
  • Ubie raised $26M (Series C) on August 22, 2022.
  • Fennec Pharmaceuticals raised $5M on August 22, 2022.

Who to call at ImmunityBio, and when

A new round usually means ImmunityBio is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day ImmunityBio raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at ImmunityBio, from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at ImmunityBio. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

ImmunityBio

Location

3530 John Hopkins Court

San Diego, California, United States

About

ImmunityBio, Inc. (formerly NantKwest, Inc.) is developing cell and immunotherapy products that are designed to help strengthen each patient’s natural immune system, potentially enabling it to outsmart the disease and eliminate cancerous or infected cells. The activation of the innate immune system is key to the development of immunological memory.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment ImmunityBio raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

2 contacts
Verified contactsJim D., National Director, Key Accounts hiddenSee plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for ImmunityBio's next move

See what Strategic adds

ImmunityBio raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.